Table 1.
Characteristics of the VV-ECMO and VA-ECMO study populations
| VV-ECMO cohort | VV-ECMO patients survived | VV-ECMO deceased patients | p value | VA-ECMO cohort | |
|---|---|---|---|---|---|
| Number of patients, n | 17 | 7 | 10 | - | 9 |
| Age, years (mean ± SD) | 48 ± 10 | 44 ± 10 | 51 ± 9 | 0.15 | 45 ± 20 |
| Men, n | 11 (65%) | 5 (71%) | 6 (60%) | 0.65 | 7 (78%) |
| Women, n | 6 (35%) | 2 (29%) | 4 (40%) | 2 (22%) | |
| BMI, kg/m2 (mean ± SD) | 33.2 ± 6.3 | 35.6 ± 4.5 | 31.5 ± 7.0 | 0.19 | 32 ± 7 |
| Diabetes mellitus, n | 11 (65%) | 3 (43%) | 8 (80%) | 0.13 | 4 (44%) |
| Hypertension, n | 9 (53%) | 4 (57%) | 5 (50%) | 0.79 | 3 (33) |
| COPD, n | 2 (12%) | 0 (0%) | 2 (20%) | 0.23 | 0 (0%) |
| Active tobacco use, n | 1 (6%) | 0 (0%) | 1 (10%) | 0.42 | 3 (33%) |
| Home ACEi/ARB/ARNI use, n | 6 (35%) | 2 (26%) | 4 (40%) | 0.65 | 1 (11%) |
| Hospital days before ECMO cannulation (median, IQR) | 7.8 (4.8–11.1) | 4.8 (2.7–8.6) | 9.3 (6.6–13.3) | 0.09 | 2.1 (0.7–1.4) |
| Prone positioning, n | 13 (76%) | 6 (86%) | 7 (70%) | 0.48 | 0 (0%) |
| P/F ratio before cannulation (median, IQR) | 65 (59–72) | 65 (59–75) | 65 (59–70) | 0.92 | 306 (163–408) |
| Days on ECMO (median, IQR) | 23 (18–37) | 18 (12–26) | 29 (21–42) | 0.20 | 7 (3–8) |
| Days of vasoactive agent use (median, IQR) | 15 (8–20) | 7 (4–8) | 19 (15–33) | 0.001 | 7 (4–8) |
| Number of RBC transfusions per days on VV-ECMO (mean ± SD) | 0.9 ± 0.4 | 0.8 ± 0.4 | 0.9 ± 0.5 | 0.84 | 0.9 ± 0.8 |
The p values listed compare differences between VV-ECMO patients.
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; BMI, body mass index; COPD, chronic obstructive pulmonary disease; P/F ratio (Horowitz index), ratio of arterial oxygen partial pressure (PaO2) to fraction of inspired oxygen (FiO2); RBC, red blood cell; VA-ECMO, venoarterial extracorporeal membrane oxygenation; VV-ECMO, venovenous extracorporeal membrane oxygenation.